Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dissecting autonomous enzymatic variability in single cells.

Nature communications·2026

Same author

Effects of echo time and modeling of compartmental T2 on VERDICT parameter estimation in brain tumors.

Magma (New York, N.Y.)·2026

Same author

Location of incidental and symptomatic LGGs. A review of comparative studies.

NeuroImage. Clinical·2026

Same author

Prevalence and patterns of biochemical discordance in patients with surgically treated acromegaly.

Pituitary·2026

Same author

Discrepancies in Inter-Rater Agreement on Resectability of Recurrent Glioblastoma: Complementary Post-hoc Analysis of the Prospective, Randomized DIRECTOR Trial.

Neuro-oncology·2026

Same author

Hemizygous deletion of <i>CDKN2A/B</i> in <i>IDH</i>-mutated glioma: Prognostic impact when adjusting for clinical factors.

Neuro-oncology advances·2026

Search research articles

Related Experiment Video

Updated: Aug 13, 2025

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Meningioma classification by immunohistochemistry: A replicability study.

Olivia Näslund¹, Anna Lipatnikova^1,2, Anna Dénes¹

¹Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

|January 23, 2023

Summary

This summary is machine-generated.

New immunohistochemistry (IHC) markers for meningioma subtypes (MG1-MG4) showed limited clinical applicability due to marker exclusivity issues. While WHO grade impacts progression-free survival (PFS) and overall survival (OS), the proposed IHC classification requires further refinement for clinical use.

Keywords:

Immunohistochemistry Meningioma Molecular marker Recurrence

More Related Videos

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Related Experiment Videos

Last Updated: Aug 13, 2025

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Area of Science:

Neuro-oncology
Tumor biology
Immunohistochemistry

Background:

Meningiomas represent a significant portion of intracranial tumors, necessitating precise classification.
Recent research identified immunohistochemistry (IHC) markers (S100B, SCGN, ACADL, MCM2) associated with distinct meningioma biological subtypes (MG1-MG4).

Purpose of the Study:

To evaluate the clinical utility of novel IHC markers for classifying meningioma subtypes.
To assess the correlation between these IHC markers and patient outcomes, including progression-free survival (PFS) and overall survival (OS).

Main Methods:

Analysis of 244 meningioma tissue samples using IHC for S100B, SCGN, ACADL, and MCM2.
Two analytical approaches were employed: one considering any staining positive, and a second requiring >10% immunopositivity.
Correlation of immunopositivity with PFS and OS was performed.

Main Results:

The second analysis set, requiring >10% immunopositivity, allowed classification of 52.0% of samples.
WHO grades 2 and 3 tumors were enriched in molecular groups MG3 and MG4.
Both molecular group and WHO grade significantly impacted PFS, while only WHO grade predicted OS.

Conclusions:

The proposed IHC-based classification system for meningioma subtypes (MG1-MG4) faced challenges in marker exclusivity, limiting its application in the studied clinical material.
In its current form, the IHC classification method demonstrates limited clinical applicability for meningiomas.